Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Announces Promotions; McClintic New CEO of Exagen; FDA Names a Director; and Others

PerkinElmer announced key management promotions yesterday that will become effective Jan. 1.


Robert F. Friel was appointed vice chairman and elected to the Board of Directors. Jeffrey D. Capello was appointed senior vice-president and chief financial officer


Prior to this, Friel was senior vice-president and then executive vice-president and chief financial officer.


Capello was vice-president of Finance, including corporate control and treasury, since 2001.

Exagen Diagnostics named James McClintic as president and chief executive officer today.


McClintic succeeds Exagen founding chief executive officer Waneta Tuttle. Tuttle will move to Southwest Medical Ventures, the venture development company she owns. Tuttle will continue as a member of the Exagen board of directors.


Before joining Exagen, McClintic served as president and chief executive officer of Esoterix, Inc. before selling the company to LabCorp, Inc. for $150 million. McClintic was regional president of eastern operations for Corning Clinical Labs, now known as Quest. He also held positions as president of SciCor, Inc., vice president of sales for the eastern zone of Bristol-Myers Squibb, and various sales and marketing management positions with E.R. Squibb & Sons, Inc.

The US Food and Drug Administration selected Gerald J. Dal Pan as director of the Office of Drug Safety in the Center for Drug Evaluation and Research last week.


Dal Pan joined the FDA in 2000 and spent three years as a medical reviewer in the Division of Anesthetic Critical Care and Addiction Drug Products before moving to CDER's Office of Drug Safety as a division director in 2003. Prior to that, Dal Pan directed clinical research for Guilford Pharmaceuticals and HHI, LLC., Clinical Research and Statistical Services. He's a part-time Assistant Professor in the Department of Neurology at John Hopkins University School of Medicine.

Patrick Langlois has joined the Supervisory Board for ExonHit Therapeutics, the company announced last week.


Langlois currently heads his own consulting firm, PJL Conseils. Prior to that he was the vice-president of the Directorate of Adventis from 2002-2005 and the executive vice-president in charge of Finance at Adventis from 2000-2004. He spent nearly 20 years working in the pharmaceutical and chemical industries with the Rhone Poulenc Group.

Thomas J. Onofrey has joined Nanostream as director of applications development, Nanostream said last week.


Onofrey most recently served as manager of R&D at Millipore, Inc. Prior to that, he was a group leader of R&D for Nanogen.


Onofrey completed his post-doctoral program at the Universityof Californiaat Irvinein synthetic methodology and natural product synthesis. He received a BA in chemistry from the College of the Holy Cross and a PhD in organic chemistry from Dartmouth.

Microchip Biotechnologies, Inc. named Barney E. Sanders as its Chief Operating Officer, the company said last week.


Previously, Sanders held positions as general manager, vice-president, and senior director at Agilent Technologies. He's also spent 13 years at Amersham Biosciences.


Sanders received a Bachelor of Sciences in biological sciences and a PhD in molecular biology from the Universityof Birminghamin the United Kingdom.

Gökhan S. Hotamisligil has joined the Scientific AdvisoryBoard for Lipomics Technologies, Inc, the company said earlier this week.


He is James S. Summons Professor of Genetics and Metabolism and the chair of the Department of Genetics and Complex Diseases at HarvardUniversity's Schoolof Public Health.


He joins Arlen Spector, Professor of Biochemistry and Internal Medicine at IowaUniversity, as the two newest members of the board. Spector joined the board in November 2004.

Clinical Data, Inc has formed a Corporate Executive Committee and appointed Israel M. Stein, Drew J. Fromkin, Caesar J. Belbel and Mark D. Shooman, the company said yesterday.


Stein has been Clinical Data's director, president and chief executive officer since its inception in 1972.


Fromkin was appointed to the newly created position of executive vice-president and chief marketing officer late last week. He was most recently president and chief executive officer of DoctorQuality, Inc. He was president and chief executive officer of Endo Surgical Devices, Inc., vice-president for Merck & Co. subsidiary, Merck-Medco Managed Care LLC.


Belbel joined Clinical Data in 2003 as vice-president and general counsel before rising to executive vice-president and chief legal officer.


Shooman joined Clinical Data as senior vice-president and chief financial officer before becoming the chief accounting officer of the company.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.